Haitang Yang1, Feng Yao1, Yang Zhao1, Heng Zhao1. 1. Department of Thoracic Surgery, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai 200030, China.
Abstract
BACKGROUND: To assess the effect of preoperative neoadjuvant therapy on resectability, downstaging, and the prognosis in patients with stage IIIA-N2 non-small cell lung cancer (NSCLC). METHODS: Eighty-four patients who underwent resections after induction therapy [76 with neoadjuvant chemotherapy (CTx) and 8 with induction chemoradiotherapy (CRTx)] for clinically evident [larger than 1 cm on computed tomography (CT)] and pathologically confirmed ipsilateral N2 positive NSCLC (stage IIIA) between January 2009 and July 2013 were reviewed retrospectively. RESULTS: Partial response (PR) was observed in 39 patients (46.4%). Standard lobectomy was performed in 63 cases (75.0%), and extensive resection was conducted in 21 cases (25.0%), including four pneumonectomies. Pathologic nodal downstaging (pN2 to pN0-1) was confirmed in 38 cases (45.2%). After induction therapy plus resection, 5-year progression-free survival (PFS) and overall survival (OS) in cases with radical resections were 37.9% and 34.2%, respectively. Patients who underwent lobectomy or pathologic nodal downstaging had better prognosis than those who had extensive resection or persistent N2 in PFS (P=0.036; P=0.025) and OS (P=0.023; P=0.024). On univariate analysis, lobectomy and pathological nodal downstaging were favourably predictive factors both in PFS and OS. Cox multivariate analyses identified only pathologic nodal downstaging to predict better PFS, and lobectomy to be significantly prognostic for OS. CONCLUSIONS: These data suggest that neoadjuvant therapy was feasible, and helpful for tumor and pathologic nodal downstaging with promising rates of survival in patients with stage IIIA-N2 NSCLC. After induction therapy, patients with potentially radical lobectomy were more likely to benefit from operation. Pathological nodal downstaging of pN2 to pN0-1, rather than clinical response was predictive of a favorable outcome, and was correlated with a better chance of survival.
BACKGROUND: To assess the effect of preoperative neoadjuvant therapy on resectability, downstaging, and the prognosis in patients with stage IIIA-N2 non-small cell lung cancer (NSCLC). METHODS: Eighty-four patients who underwent resections after induction therapy [76 with neoadjuvant chemotherapy (CTx) and 8 with induction chemoradiotherapy (CRTx)] for clinically evident [larger than 1 cm on computed tomography (CT)] and pathologically confirmed ipsilateral N2 positive NSCLC (stage IIIA) between January 2009 and July 2013 were reviewed retrospectively. RESULTS: Partial response (PR) was observed in 39 patients (46.4%). Standard lobectomy was performed in 63 cases (75.0%), and extensive resection was conducted in 21 cases (25.0%), including four pneumonectomies. Pathologic nodal downstaging (pN2 to pN0-1) was confirmed in 38 cases (45.2%). After induction therapy plus resection, 5-year progression-free survival (PFS) and overall survival (OS) in cases with radical resections were 37.9% and 34.2%, respectively. Patients who underwent lobectomy or pathologic nodal downstaging had better prognosis than those who had extensive resection or persistent N2 in PFS (P=0.036; P=0.025) and OS (P=0.023; P=0.024). On univariate analysis, lobectomy and pathological nodal downstaging were favourably predictive factors both in PFS and OS. Cox multivariate analyses identified only pathologic nodal downstaging to predict better PFS, and lobectomy to be significantly prognostic for OS. CONCLUSIONS: These data suggest that neoadjuvant therapy was feasible, and helpful for tumor and pathologic nodal downstaging with promising rates of survival in patients with stage IIIA-N2NSCLC. After induction therapy, patients with potentially radical lobectomy were more likely to benefit from operation. Pathological nodal downstaging of pN2 to pN0-1, rather than clinical response was predictive of a favorable outcome, and was correlated with a better chance of survival.
Entities:
Keywords:
Non-small cell lung cancer (NSCLC); downstaging; neoadjuvant; surgery; survival
Authors: J A Roth; E N Atkinson; F Fossella; R Komaki; M Bernadette Ryan; J B Putnam; J S Lee; H Dhingra; L De Caro; M Chasen; W K Hong Journal: Lung Cancer Date: 1998-07 Impact factor: 5.705
Authors: Gail E Darling; Fei Li; Demetris Patsios; Christine Massey; Adam G Wallis; Linda Coate; Shaf Keshavjee; Andrew Pierre; Marc De Perrot; Kazuhiro Yasufuku; Marcelo Cypel; Tom Waddell Journal: Eur J Cardiothorac Surg Date: 2015-01-06 Impact factor: 4.191
Authors: Matthew Koshy; Stacey A Fedewa; Renu Malik; Mark K Ferguson; Wickii T Vigneswaran; Lawrence Feldman; Andrew Howard; Khaled Abdelhady; Ralph R Weichselbaum; Katherine S Virgo Journal: J Thorac Oncol Date: 2013-07 Impact factor: 15.609
Authors: N Lorent; P De Leyn; Y Lievens; E Verbeken; K Nackaerts; C Dooms; D Van Raemdonck; B Anrys; J Vansteenkiste Journal: Ann Oncol Date: 2004-11 Impact factor: 32.976
Authors: Michael Peer; David Stav; Arnold Cyjon; Judith Sandbank; Margarita Vasserman; Zoya Haitov; Lior Sasson; Letizia Schreiber; Tiberiu Ezri; Israel E Priel; Henri Hayat Journal: Heart Lung Circ Date: 2014-07-14 Impact factor: 2.975
Authors: D C Betticher; S-F Hsu Schmitz; M Tötsch; E Hansen; C Joss; C von Briel; R A Schmid; M Pless; J Habicht; A D Roth; A Spiliopoulos; R Stahel; W Weder; R Stupp; F Egli; M Furrer; H Honegger; M Wernli; T Cerny; H-B Ris Journal: Br J Cancer Date: 2006-04-24 Impact factor: 7.640
Authors: Jessica Glover; Frank O Velez-Cubian; Kavian Toosi; Emily Ng; Carla C Moodie; Joseph R Garrett; Jacques P Fontaine; Eric M Toloza Journal: J Thorac Dis Date: 2016-08 Impact factor: 2.895
Authors: Bo Deng; Tianyu Sun; Bo Tang; Shaolin Tao; Poming Kang; Kai Qian; Bin Jiang; Kun Li; Kunkun Li; Jinghai Zhou; Ruwen Wang; Qunyou Tan Journal: Oncotarget Date: 2017-11-06
Authors: K Sinn; B Mosleh; A Steindl; S Zoechbauer-Mueller; K Dieckmann; J Widder; E Steiner; W Klepetko; K Hoetzenecker; V Laszlo; B Doeme; T Klikovits; M A Hoda Journal: ESMO Open Date: 2022-04-06